Keeping cancer
in check

<p>Middle aged man running in a field of grass, surrounded by mountains.</p>

More cancer patients than ever before experience an initial treatment success, leading to clinical remission of the disease. However, tumor recurrence is an imminent threat and responsible for the majority of cancer-related deaths. At Mendus, we focus on therapies addressing tumor recurrence.


Our Approach

Our goal is to provide novel maintenance therapy solutions with best-in-class safety profiles for tumors associated with a high recurrence rate. Via relapse vaccination, we aim to boost immunity against residual disease, in order to extend the periods of cancer-free survival.
Recurred tumors often respond poorly to existing therapies and many of such cancers have evolved to evade the immune system. Via intratumoral immune priming, we can unveil these tumors, making them more vulnerable to immune attack.

Cancer Treatment Today

AML Maintenance

In acute myeloid leukemia (AML), maintenance treatment is the new frontier.
Measurable residual disease (MRD) is associated with poor relapse-free and overall survival.
Relapse vaccination with DCP-001 is being evaluated in a Phase 2 clinical trial addressing AML patients with MRD.

Ovarian Cancer

Ovarian cancer is the most common cause of death among gynecologic malignancies, due to its high recurrence rate.
A Phase 1 clinical trial is ongoing to evaluate DCP-001 safety and efficacy in ovarian cancer.
If successful, the trial supports development of an ovarian cancer maintenance therapy.

Intratumoral Priming

Mendus is evaluating a clinical trial to explore the intratumoral immune primer ilixadencel as a second-line treatment for gastrointestinal stromal tumors (GIST), in combination with standard-of-care.
After first-line treatment fails, GIST responds poorly to currently available therapies.
Ilixadencel has demonstrated clinical signs of efficacy in a broad range of solid tumors, including GIST.

<p>Image of a person front crawling in dark water. Mountains and dark clouds are seen in the background.</p>

AML Maintenance

In acute myeloid leukemia (AML), maintenance treatment is the new frontier.
Measurable residual disease (MRD) is associated with poor relapse-free and overall survival.
Relapse vaccination with DCP-001 is being evaluated in a Phase 2 clinical trial addressing AML patients with MRD.

Ovarian Cancer

Ovarian cancer is the most common cause of death among gynecologic malignancies, due to its high recurrence rate.
A Phase 1 clinical trial is ongoing to evaluate DCP-001 safety and efficacy in ovarian cancer.
If successful, the trial supports development of an ovarian cancer maintenance therapy.

Intratumoral Priming

Mendus is evaluating a clinical trial to explore the intratumoral immune primer ilixadencel as a second-line treatment for gastrointestinal stromal tumors (GIST), in combination with standard-of-care.
After first-line treatment fails, GIST responds poorly to currently available therapies.
Ilixadencel has demonstrated clinical signs of efficacy in a broad range of solid tumors, including GIST.


Pipeline

ADVANCE II

Indication

Acute myeloid leukemia

Product

DCP-001 (monotherapy)

Status

Ongoing, multiple updates in 2022
Orphan Drug Designation

  • Preclinical
  • Phase I
  • Phase II
  • Phase III

TROY

Indication

Gastro-intestinal stromal tumors

Product

Ilixadencel (kinase inhibitors)

Status

In preparation, start in 2022
Fast Track & Orphan Drug Designation

  • Preclinical
  • Phase I
  • Phase II
  • Phase III

ALISON

Indication

Ovarian cancer

Product

DCP-001 (monotherapy)

Status

Ongoing, initial data accepted for presentation at ESGO 2022

  • Preclinical
  • Phase I
  • Phase II
  • Phase III

ADVANCE II

Indication

Acute myeloid leukemia

Product

DCP-001 (monotherapy)

Status

Ongoing, multiple updates in 2022
Orphan Drug Designation

  • Preclinical
  • Phase I
  • Phase II
  • Phase III

TROY

Indication

Gastro-intestinal stromal tumors

Product

Ilixadencel (kinase inhibitors)

Status

In preparation, start in 2022
Fast Track & Orphan Drug Designation

  • Preclinical
  • Phase I
  • Phase II
  • Phase III

ALISON

Indication

Ovarian cancer

Product

DCP-001 (monotherapy)

Status

Ongoing, initial data accepted for presentation at ESGO 2022

  • Preclinical
  • Phase I
  • Phase II
  • Phase III

Ongoing Clinical Trials

If you are a patient or a treating physician interested in any of the ongoing clinical trials, please contact us at info@mendus.com. All ongoing trials are also listed on clinicaltrials.gov.

Expanded Access

Mendus AB is committed to discovering and developing novel safe and effective cell therapy products for solid tumors and blood-borne cancers to improve survival outcomes and quality of life by priming and boosting the patient’s own immune system to fight cancer.
The following is Mendus’ global expanded access policy for investigational therapies, e.g. ilixadencel (INN) and DCP-001, that are intended to treat serious diseases.


Applying dendritic cell biology to design novel cancer immunotherapies

Dendritic cells orchestrate the immune system, including the immune surveillance of potential cellular aberrations which could lead to cancer.

Increasing evidence suggests that dynamic interactions between dendritic cells, involving cellular crosstalk and the exchange of cellular content, are crucial in fulfilling this task.

At Mendus, we apply these insights in dendritic cell biology to design novel immunotherapies and unlock meaningful clinical benefits for cancer patients.

<p>Close up of a female, dropping liquid from a pipette into a glass jar.</p>

The cancer relapse vaccine DCP-001 is derived from a proprietary cancer cell line. During manufacturing, these cancer cells are made to express dendritic cell molecules on their surface, rendering them highly immunogenic and suitable as a vaccine.

The intratumoral immune primer ilixadencel comprises pro-inflammatory dendritic cells from healthy donor material, which are injected into the tumor. This leads to local inflammation in the tumor microenvironment and the triggering of systemic anti-tumor immunity.

Our preclinical pipeline focuses on the design of next-generation products and novel combination therapies, including the combination of vaccination and intratumoral priming.

Publications